USFDA issues warning letter to Aurobindo Telangana plant

USFDA issues warning letter to Aurobindo Pharma's Telangana facility. The regulator cited data integrity issues and current Good Manufacturing Practice (cGMP) violations. This may lead to import alerts or shipment delays to the US market. Export-heavy operations could face revenue impact if unresolved.

📊 STOCKS: $AUROPHARMA | 🏢 SECTOR: Pharma | #HIGHIMPACT #FDA